6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
ID: NOI-CC-25-000022Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/6082db041c2344fe9f3e55372b2752f2/view
Timeline
  1. 1
    Posted Apr 15, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 15, 2025, 12:00 AM UTC
  3. 3
    Due Apr 21, 2025, 3:00 PM UTC
Description

The National Institutes of Health (NIH) intends to procure six months' supply of Sirturo (Bedaquiline) tablets through a sole-source contract with Cardinal Health, as part of its pharmaceutical care services for patients in clinical trials. The requirement includes approximately 12 to 36 bottles of 100 mg tablets in 188-count bottles and 20 mg tablets in 60-count bottles, with the expectation of needing up to 10 bottles of the former and up to 3 bottles of the latter per year. Sirturo is critical for patient care, as it is the only medication available for specific treatment needs, and Cardinal Health is the sole distributor authorized by the manufacturer, Janssen Therapeutics. Interested parties may submit capability statements by April 21, 2025, to Lu Chang at lu-chang.lu@nih.gov, as this is not a request for proposals.

Point(s) of Contact
Lu Chang
lu-chang.lu@nih.gov
Files
No associated files provided.
Lifecycle
Title
Type
6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
Currently viewing
Presolicitation
Similar Opportunities
Notice of Intent to Sole Source – TheraDoc subscription
Buyer not available
The National Institutes of Health (NIH) Clinical Center intends to award a firm fixed-price purchase order for subscription services related to the TheraDoc application, exclusively owned by Premier Healthcare LLC. This procurement aims to secure applications, support, maintenance, and training for the TheraDoc clinical surveillance solution, which is critical for enhancing healthcare delivery and patient safety. The acquisition will follow the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for a sole-source solicitation due to the unique nature of the services required. Interested parties may express their capabilities and submit comments to the NIH by November 21, 2024, with inquiries directed to Ryssa Nix at Ryssa.nix@nih.gov.
6505--Ranolazine Sustained Action (SA) Tablets
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Ranolazine Sustained Action Tablets, a pharmaceutical product essential for veteran healthcare. Bidders are required to submit pricing for a base year and four option years, along with compliance documentation including National Drug Code (NDC) numbers and adherence to packaging specifications as mandated by the Drug Supply Chain Security Act. This procurement underscores the government's commitment to ensuring a reliable supply of quality medications while adhering to federal standards, including Good Manufacturing Practices (cGMP). Interested parties should contact Contract Specialist Deborah S. Fassl at Deborah.Fassl@va.gov for further details regarding submission requirements and deadlines.
Notice of Intent to Award a Sole Source BPA
Buyer not available
The Defense Health Agency (DHA) intends to award a Sole Source Blanket Purchase Agreement (BPA) to Broughton Pharmaceuticals, LLC for the procurement of specialty pharmaceuticals, including oral, injectable, and inhalation forms. This procurement is being conducted under FAR 13.501(a)(1), indicating that no competitive solicitations will be available at this time, and it aims to ensure the military healthcare system has access to essential specialized health services and products. Interested parties may submit capability statements by April 30, 2025, at 2:00 PM EST, to the designated contacts, Oneil Sharpe and Mrs. Faatalivale M. Te’o-Lewis, for consideration regarding potential competitive procurement, although the final decision will rest with the government.
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Topiramate Tablets under the contract number VA-25-00047941. This procurement aims to ensure a consistent supply of essential pharmaceuticals, including Topiramate and Tadalafil, to support various government healthcare programs, including the Department of Defense and the Indian Health Service. Offerors are required to comply with the Drug Supply Chain Security Act (DSCSA), including specific packaging, labeling standards, and rigorous cGMP compliance, while submitting pricing for the base year and four option years. Interested parties should contact Contract Specialist Billy Fong at Billy.Fong@va.gov for further details and to participate in the proposal submission process.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Rabeprazole Sodium Delayed Release Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
FINIA 2.0 Fill Finish Equipment – Terumo BCT, Inc
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Terumo BCT, Inc. for the procurement of one FINIA 2.0 Fill Finish Equipment unit. This equipment is critical for the preparation and cryopreservation of cellular therapy doses, addressing risks associated with manual processes that could lead to inadequate dosing and severe side effects. The FINIA 2.0 device is uniquely designed to handle volumes from 2 mL to 100 mL while complying with current Good Manufacturing Practices (cGMP), making it essential for the NIH's new Center for Cellular Engineering facilities in Bethesda, Maryland. Interested parties may submit capability statements to Damien Goines at damien.goines@nih.gov by May 5, 2025, at 9:00 AM (EST).
6505--Carvedilol Tablets (VA-25-00048048)
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Carvedilol Tablets under solicitation number 36E79725R0028, with an amendment extending the submission deadline to May 1, 2025, at 2:30 PM Central Daylight Time. Offerors are required to provide pricing for various types of Carvedilol Tablets, submit unique National Drug Code (NDC) numbers, and comply with federal regulations, including the Drug Supply Chain Security Act (DSCSA) and FDA manufacturing standards. This procurement is crucial for ensuring a reliable supply of pharmaceuticals to enhance healthcare services for veterans and active duty military personnel. Interested contractors should direct their proposals to the specified VA email addresses and acknowledge receipt of the amendment to remain eligible for consideration.
Rabeprazole Sodium DR
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Rabeprazole Sodium DR 20MG Tablets. This procurement aims to fulfill the pharmaceutical needs of military personnel, emphasizing compliance with federal acquisition regulations and ethical conduct in contractor performance. Interested vendors must submit their proposals via the DLA's Internet Bid Board System (DIBBS) by May 15, 2025, and are encouraged to reach out to primary contact Trong Nguyen at Trong.Nguyen@dla.mil or secondary contact Jason Wray at jason.wray@dla.mil for further inquiries.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.